Cargando…
Comparison of nifekalant and amiodarone for resuscitation of out-of-hospital cardiopulmonary arrest resulting from shock-resistant ventricular fibrillation
PURPOSE: Nifekalant is a pure potassium channel blocker that has been used to treat ventricular tachyarrhythmias since 1999 in Japan. Intravenous amiodarone was approved later than nifekalant in Japan, and it is still unclear which of the two agents is superior. The aim of this study was to compare...
Autores principales: | Harayama, Nobuya, Nihei, Shun-ichi, Nagata, Keiji, Isa, Yasuki, Goto, Kei, Aibara, Keiji, Kamochi, Masayuki, Sata, Takeyoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Japan
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4126999/ https://www.ncbi.nlm.nih.gov/pubmed/24389941 http://dx.doi.org/10.1007/s00540-013-1775-5 |
Ejemplares similares
-
Comparison of nifekalant and amiodarone for resuscitation after cardiopulmonary arrest due to shock-resistant ventricular fibrillation
por: Harayama, N, et al.
Publicado: (2011) -
Bacteremia affects the mortality of septic patients with high serum procalcitonin level in the ICU
por: Kamochi, M, et al.
Publicado: (2012) -
Catecholamine index is a simple and useful marker for bacteremic patients treated by polymyxin B hemoperfusion therapy
por: Isa, Y, et al.
Publicado: (2011) -
Nifekalant versus Amiodarone for Out-Of-Hospital Cardiac Arrest with Refractory Shockable Rhythms; a Post Hoc Analysis
por: Funakoshi, Hiraku, et al.
Publicado: (2022) -
Meta-analysis of the efficacies of amiodarone and nifekalant in shock-resistant ventricular fibrillation and pulseless ventricular tachycardia
por: Sato, Shiho, et al.
Publicado: (2017)